Custom crystal, incorporating a pharma vial design, celebrating the successful initial public offering on the Euronext Growth Oslo exchange of Oncoinvent. The Oslo-based company is focused on cancer treatments. (25LNL007)
Custom crystal, incorporating a pharma vial design, celebrating the successful initial public offering on the Euronext Growth Oslo exchange of Oncoinvent. The Oslo-based company is focused on cancer treatments. (25LNL007)
Crystal deal tombstone, incorporating two logo cutouts, marking the acquisition of two Missouri-based manufacturers of surgical instruments. (22ALJ096)
Crystal deal tombstone celebrating Series A funding for Gather Heath, a Massachusetts-based primary care practice focused on older adults. (24AZH136)
Custom Lucite deal toy, replicating a spray bottle product, commemorating a follow-on stock offering by Novabay Pharmaceuticals. The Emeryville, California-based biopharmaceutical company develops products for the eye care market. (24AKL343)
Crystal deal toy recognizing a follow-on public stock offering by Autonomix Medical. The Texas-based company specializes in technologies aimed at diagnosing and treating diseases involving the nervous systems. (24AKL507)
Pill-shaped crystal award recognizing excellence in safety and operational performance. (24AZH129)
Custom Lucite, incorporating an embedded vial of Imdelltra, celebrating the approval of the drug by the Food and Drug Administration (FDA). Developed by Amgen, Imdelltra treats small cell lung cancer, a condition that afflicts about 35,000 Americans annually. (24ALJ148)
Lucite deal toy, featuring a reverse-etched lasered logo, marking the acquisition of Alpine Laser. The company specializes in laser technology for medical devices. (24AKL389)
Custom Lucite celebrating the first-in-human trial of SOR 102, a treatment for nflammatory bowel disease. The drug was developed by Utah-based Sorriso Pharmaceuticals. (23AKL435)
